About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 68337 record(s)
Req # A-2023-000758
Adverse Drug Reactions (ADRs). Report numbers: E2B_03583301, E2B_06442226, E2B_06413944, E2B_06442785, E2B_06438176, E2B_06452366, E2B_06421208, E2B_06428678, E2B_06418609.Organization: Health Canada
January 2024
Req # A-2023-000763
Adverse Drug Reactions (ADRs). Report numbers: E2B_06425916, E2B_06426700, E2B_06428262, E2B_06428379.Organization: Health Canada
January 2024
Req # A-2023-000779
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-102700- 258.Organization: Health Canada
January 2024
Req # A-2023-000784
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-106488-990.Organization: Health Canada
January 2024
Req # A-2023-000836
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-101473-308.Organization: Health Canada
January 2024
Req # A-2023-000837
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-103099-693.Organization: Health Canada
January 2024
Req # A-2023-000847
Adverse Drug Reactions (ADRs) for Tavneos. Report numbers: E2B_06476280, E2B_06503137. ADR for Rexulti: E2B_06469898. ADR for Rexulti. Report number: E2B_06469898. ADR for Rexulti and Aripiprazole. Report number: E2B_06501539. ADRs for Ablify…Organization: Health Canada
January 2024
Req # A-2023-000848
Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_00539952, E2B_00897836, E2B 00941720, E2B_01562153, E2B_01565942, E2B_02147049, E2B_01141776, E2B_00622627, E2B_01124955, 000649045.Organization: Health Canada
January 2024
Req # A-2023-000885
Adverse Drug Reactions (ADRs). Report numbers: E2B_05723103, 001047899, 001049502, 001051502, E2B_06524635, E2B_06515895, E2B_06523800.Organization: Health Canada
January 2024
Req # A-2023-000887
Adverse Drug Reactions (ADRs). Report numbers: E2B_03502706, 001035382, 001027439, 001033519, 001023452, E2B_02076775, E2B_06026557, E2B_05463299, E2B_06044179, E2B_06257918.Organization: Health Canada
January 2024